Sputnik V was registered in India underneath the emergency use authorization process on April 12, 2021
Panacea Biotech shares hit the higher circuit of 5 per cent at Rs 406.10 on the BSE after the Panacea Biotech and the Russian Direct Investment Fund (RDIF) introduced the launch of manufacturing of the Russian Sputnik V vaccine towards coronavirus.
“The first batch produced at the company’s facilities at Baddi will be shipped to the Gamaleya Center for quality control. Full-scale production of the vaccine is due to start this summer, Company’s facilities comply with Good Manufacturing Practice (GMP) standards and are prequalified by World Health Organization (WHO),” Panacea Biotech stated in a regulatory submitting to the inventory exchanges.
Sputnik V was registered in India underneath the emergency use authorization process on April 12, 2021 and vaccination towards coronavirus with the Russian vaccine began on May 14.
RDIF and Panacea will producing 100 million doses of Sputnik V per 12 months.
The Sputnik V vaccine relies on human adenoviral vectors platform and makes use of two completely different vectors for the 2 photographs in a course of vaccination, offering immunity with an extended length than vaccines utilizing the identical supply mechanism for each photographs, the corporate stated.
The BSE Sensex and NSE Nifty have been buying and selling greater by 0.3 per cent on the time.
